CN113969283B - Site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof - Google Patents
Site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof Download PDFInfo
- Publication number
- CN113969283B CN113969283B CN202111395490.6A CN202111395490A CN113969283B CN 113969283 B CN113969283 B CN 113969283B CN 202111395490 A CN202111395490 A CN 202111395490A CN 113969283 B CN113969283 B CN 113969283B
- Authority
- CN
- China
- Prior art keywords
- protein
- site
- gene
- expression
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
Abstract
The invention discloses a site for stably expressing protein in a CHO cell gene NW _003613756.1 and application thereof, wherein the stable expression site obtained by the invention is positioned at the base within the range of 150bp upstream and downstream of the 101424 th base of the CHO cell gene NW _003613756.1, namely the 101274 + 101574 base, and can integrate a foreign protein gene and carry out stable expression. The target gene is integrated into the stable expression region in a fixed-point integration mode, so that the problem of uncertain integration sites caused by random integration is solved; the invention overcomes the expression instability caused by position effect and the repeated and fussy cell strain screening process by integrating the exogenous gene at the position of 101424 bases of the stable expression site NW _003613756.1 and in the range of upstream 101274-101574 bases in the CHO genome.
Description
Technical Field
The invention relates to a site for stably expressing protein in a CHO cell gene NW _003613756.1 and application thereof, belonging to the technical field of genes.
Background
Chinese Hamster Ovary (CHO) cells were established in the laboratory of dr. theodore t. puck in 1957, are immortalized, non-secreting cells that secrete little endogenous protein; meanwhile, the protein has the advantages of more approximate post-translational modification to human natural protein, difficult infection by human viruses, large-scale culture in serum-free culture medium with definite chemical components and the like, so that the protein is widely applied to the field of biological pharmacy, and more than 70 percent of protein medicines are produced. However, CHO cells have long culture period and high culture cost as mammalian cells, and meanwhile, the demand for recombinant products such as monoclonal antibodies is increasing, and the continuously increasing demand means that the specific productivity needs to be optimized. Although the expression quantity can be improved by increasing the copy number of genes, developing a new strong promoter, searching a proper enhancer and the like, the expression level of most CHO cells in the long-term culture process is unstable, and the problems of product approval and product marketing of a supervision department are directly influenced. Therefore, the construction of stable and high expression CHO expression strain is very important for the research and development of protein drugs and the marketing.
There are two strategies for constructing stable and highly expressed cell lines. One is the traditional method of combining random integration with high-throughput screening, and the other is the method of combining gene editing technology with homologous directed repair to integrate the target gene into a predetermined chromosomal locus in a fixed-point manner. However, due to uncertainty of integration sites and existence of position effects, the constructed cell genotypes have great difference in random integration, and the problem of unstable expression is easily caused in the long-term passage process, so that the later screening process is very long, and the whole process of generating the recombinant cell line by a random integration mode in an industrial environment usually needs 6-12 months; compared with random integration, the site-directed integration utilizes a gene editing technology, particularly a genome site-directed editing technology widely applied in recent years and mediated by CRISPR/Cas9, greatly reduces the development time and cost, and because the sequence is known, the information after the site-directed integration is clearer and more definite than the information after the random integration.
Random integration is the most mature traditional method for constructing a protein expression system, but multiple screening is needed to obtain a stable high-expression cell strain in a random integration mode, so that the time consumption is long, and the cost is high. Meanwhile, for the cell line obtained by random integration, the loss of expression stability of the cells in the later period of culture cannot be predicted at all: such instability may not occur at all; it is also possible that the cells develop after an infinite number of divisions; it is also possible that after the cell has divided for only a few passages, significant instability occurs. The stability problem not only affects the time of the product on the market, but also conflicts with the drug regulation management. In addition, the information of random integration sites is unclear, and the site effect of exogenous gene integration can also cause the expression level of the target gene to be remarkably reduced. According to the existing literature reports, the instability of the recombinant CHO cell line appears in all recombinant CHO cell lines, and the problem of unstable expression becomes an extremely common problem.
Disclosure of Invention
In order to solve the technical problems, the invention provides a site for stably expressing protein in a CHO cell genome, the site has clear information, the site can realize the site-specific integration of protein genes, can stably express the protein, can greatly shorten the screening process and time in the cell construction process, and reduces the research and development cost.
The first objective of the invention is to provide a site for stably expressing a protein in the CHO cell genome, wherein the site for stably expressing the protein is located within the 101274-101574 of the CHO cell gene NW _ 003613756.1.
Further, the nucleotide sequence of the 101274-101574 bases of the CHO cell gene NW _003613756.1 is shown as SEQ ID NO. 1.
Further, when the CRISPR/Cas9 technology is used for site-directed transfer of a coding gene of a target protein, the site for stably expressing the protein can be recognized by a 5'NNNNNNNNNNNNNNNNNNNNNGG 3' sequence of the CRISPR/Cas9 technology.
In the present invention, this site is located at the intron of the cep170 gene on the CHO cell genome NW _ 003613756.1.
Further, in the embodiment of the present invention, the 5'NNNNNNNNNNNNNNNNNNNNNGG 3' sequence is selected from the following 9 groups of sequences: 5'-TTCTTTTATGACATTCCCACTGG-3', 5'-ATATGTTCAAAGTTCACCAGTGG-3', 5'-ACTTTGAACATATTTCAGTGGGG-3', 5'-GAGATTTAAAAGTCATATGCAGG-3', 5'-GTTGGAAAAAAAATAAAATTTGG-3', 5'-CAACTTTTTTTATTTGAATTAGG-3', 5'-TTTTTATTTGAATTAGGAACAGG-3', 5'-ATGGGTAGGAGAAGGGAAATGGG-3', 5'-GCAGGTAGGGGAGGATGGGTAGG-3'.
In the present invention, the above-mentioned 9 sequences cover most of the upstream and downstream sequences within 300 bases of the present invention within the 101274-101574 base of the CHO cell gene NW-003613756.1, indicating that 300 bases of the present invention can be used as sites for stably expressing proteins.
The present invention is not limited to the above 9 sequences, but the above 9 sequences are only preferred technical means for introducing the gene encoding the target protein into the stable expression site, and the purpose of stably expressing the protein of the present invention can be achieved by using other sequences, even other means for introducing the target gene.
Further, the protein is a protein with a molecular weight of less than 160 KDa.
Further, the protein is one of polypeptide, functional protein, antibody and fusion protein.
The second purpose of the invention is to provide the application of the site for stably expressing the protein in the CHO cell genome in the stable expression of the foreign protein by the CHO cells.
Furthermore, the application specifically comprises constructing a foreign protein or polypeptide encoding gene at a site where the protein is stably expressed in the CHO cell gene NW _ 003613756.1.
The third purpose of the invention is to provide an expression vector for expressing protein in CHO cells, wherein the coding gene of the protein is positioned in the middle region of a 5 'homologous arm and a 3' homologous arm on the expression vector, and the 5 'homologous arm and the 3' homologous arm are respectively sequences with the upstream and downstream length of 600bp of the site for stably expressing the protein.
In the invention, the expression vector is a vector suitable for CHO cell expression.
Furthermore, the expression vector also comprises a promoter sequence positioned at the upstream of the coding gene of the protein, and the promoter controls the expression of the protein.
Further, the promoter is: CMV (a strong mammalian expression promoter derived from human cytomegalovirus), EF-1a (a strong mammalian expression promoter derived from human elongation factor 1 α), SV40 (a mammalian expression promoter derived from simian vacuolating virus 40), PGK1 (a mammalian promoter derived from phosphoglycerate kinase gene), UBC (a mammalian promoter derived from human ubiquitin C gene), human beta actin (a mammalian promoter derived from β -actin gene), CAG (a strong hybrid mammalian promoter), and the like.
In the present invention, a method for constructing an expression vector for expressing a protein in a CHO cell is also included, comprising the steps of: inserting the coding gene of the protein into the region between 5 'arm and 3' arm of the plasmid, and enabling the coding gene of the protein to be positioned at the downstream of the promoter and to be controlled by the promoter to obtain the expression vector for expressing the protein in the CHO cell.
The fourth purpose of the invention is to provide a CHO recombinant cell which can stably express protein in a fixed-point integration way, wherein the CHO recombinant cell is obtained by transferring the expression vector for expressing the protein in the CHO cell, sgRNA plasmid corresponding to a target sequence and Cas9 plasmid into the CHO cell.
Further, the target sequence is preferably 5'-TTCTTTTATGACATTCCCACTGG-3', 5'-ATATGTTCAAAGTTCACCAGTGG-3', 5'-ACTTTGAACATATTTCAGTGGGG-3', 5'-GAGATTTAAAAGTCATATGCAGG-3', 5'-GTTGGAAAAAAAATAAAATTTGG-3', 5'-CAACTTTTTTTATTTGAATTAGG-3', 5'-TTTTTATTTGAATTAGGAACAGG-3', 5'-ATGGGTAGGAGAAGGGAAATGGG-3' or 5'-GCAGGTAGGGGAGGATGGGTAGG-3'.
In the present invention, there is also provided a method for constructing a CHO recombinant cell, comprising the steps of:
(1) transfecting the plasmid vector into a CHO cell by a liposome transfection mode to obtain a recombinant CHO cell pool;
wherein, the plasmids are the expression vector for expressing the protein in the CHO cell, the sgRNA plasmid corresponding to the target sequence and the Cas9 plasmid respectively;
(2) screening the recombinant cell pool to obtain a CHO recombinant cell expressing the foreign protein;
(3) culturing CHO recombinant cells in an adherent manner, detecting the expression level of protein, and performing suspension domestication on high-expression adherent CHO recombinant cells;
(4) and (3) culturing and verifying stability of the suspension domesticated CHO recombinant cell, and detecting the expression level of the protein.
The invention has the beneficial effects that:
the stable expression site obtained by the invention is located in the range of 150bp upstream and downstream of the 101424 th base of the CHO cell gene NW _003613756.1, namely the 101274-101574 base, and can integrate the foreign protein gene and carry out stable expression. The target gene is integrated into the stable expression region in a fixed-point integration manner, so that the problem of undefined integration site caused by random integration is solved; according to the invention, the exogenous gene is integrated at a fixed point in the range of the upstream and downstream 101274-101574 bases at the 101424 base of the stable expression site NW _003613756.1 in the CHO genome, so that the expression instability caused by position effect and the repeated and tedious screening process of cell strains are overcome, the original screening time of 6-12 months is reduced to 1-3 months, the research and development time for constructing a stable expression cell line is effectively shortened, and the cost is reduced.
Description of the drawings:
FIG. 1 is a schematic diagram of a fixed point integration according to the present invention;
FIG. 2 shows the EGFP expression of cells constructed with different target sequences in different generations.
FIG. 3 shows IL2-HSA expression in cells constructed with different target sequences in different generations.
Detailed Description
The present invention is further described below in conjunction with specific examples to enable those skilled in the art to better understand the present invention and to practice it, but the examples are not intended to limit the present invention.
The related detection method comprises the following steps:
the method for measuring the average fluorescence intensity of the cells comprises the following steps: culturing the cells until the confluence reaches about 90%, digesting the cells by using 0.25% trypsin, terminating the digestion by using a complete culture medium with the same amount as the trypsin, collecting the cells in a sterile centrifuge tube, centrifuging for 5min at 1000rpm/min, discarding the supernatant, resuspending the cells by using PBS, collecting the cells in a flow-type sample tube through a cell filter screen, and analyzing the fluorescence intensity of the cells by using a flow cytometer by using a blank CHO-K1 cell as a control.
Example 1: screening for Stable expression sites
The CHO-K1-1b7 cells which are screened by a flow cytometer in high flux and express Zsgreen1 reporter genes are cultured to be in a good state under an adherent culture state, the CHO cells at the time are regarded as 0 generation, the CHO cells are continuously cultured for 20 generations, the conditions that the cells express Zsgreen1 protein at 0, 10 and 20 generations are observed under an inverted fluorescence microscope, and meanwhile, the average fluorescence intensity of the cells at 0, 10 and 20 generations is detected by a BD flow cytometer.
Through observation by an inverted fluorescence microscope and detection by a flow cytometer, after 20 generations of continuous passage, the CHO-K1-1b7 cells still can express Zsgreen1 protein in percentage under the adherent culture state, and the expression levels of the Zsgreen1 protein among different generations are basically consistent and have strong green fluorescence signals.
Suspension domestication was performed on CHO-K1-1b7 cells verified for adherence stability, and 60 serial passages were performed on CHO-K1-1b7 cells successfully subjected to suspension domestication, and the cells were used as the 0 th passage when suspension domestication was successful. And observing the Zsgreen1 protein expression condition of the cells at 0 th, 10 th, 20 th, 30 th, 40 th, 50 th and 60 th generations under an inverted fluorescence microscope, and simultaneously detecting the average fluorescence intensity of the cells at 0 th, 10 th, 20 th, 30 th, 40 th, 50 th and 60 th generations by using a flow cytometer.
Through observation of an inverted fluorescence microscope and detection of a flow cytometer, after 60 generations of continuous passage, the CHO-K1-1b7 cells can still express Zsgreen1 protein in percentage under the suspension culture state, and the expression levels of the Zsgreen1 protein among different generations are basically consistent and have strong green fluorescence signals. The CHO-K1-1b7 cell is shown to be capable of stably expressing the Zsgreen1 reporter gene, and simultaneously, the integrated site of the lentivirus carrying the Zsgreen1 reporter gene is shown to be a stable expression site.
Example 2: lentiviral integration site analysis
The Integration Site of the lentiviral vector in CHO-K1-1b7 cells was analyzed using the Lenti-X Integration Site Analysis Kit (Clontech:631263) related to chromosome walking technology, and the specific steps were as follows:
(1) construction of lentivirus integration library
Collecting CHO-K1-1b7 cells, extracting a genome by using a DNA extraction kit, and carrying out enzyme digestion on the genome for 16-18h at 37 ℃ by using three restriction enzymes of DraI, SspI and HpaI respectively, wherein the enzyme digestion system is as follows:
purifying and recovering the product after enzyme digestion by using a PCR purification kit, and connecting a chromosome walking joint genomeWalker adapter to two ends of the purified enzyme digestion fragment, wherein the connection system is as follows:
after incubation at 16 ℃ overnight and at 70 ℃ for 5 minutes and termination of the reaction, 32. mu.l of TE (10/1, pH 7.5) was added to the system to obtain three lentivirus integration libraries.
(2) PCR amplification of lentivirus integration libraries
Two rounds of nested PCR were performed on each of the three lentivirus integration libraries obtained in step (1) of example 2. Using the adaptor primers AP1 and AP2 and the lentiviral sequence-specific primers LSP1 and LSP2 of the adaptor ligated in step (1) in example 2, LTR region was amplified from the adjacent genomic region of CHO-K1 cells
The one-round PCR reaction system is as follows:
the reaction procedure was as follows:
mu.l of one round of PCR product was diluted to 50. mu.l with deinized H2O.
The two-round PCR reaction system is as follows:
the reaction procedure was as follows:
(3) sequencing and analysis
The two rounds of PCR products were subjected to agarose gel electrophoresis and gel recovery sequencing, which was performed according to the Lenti-integration Site Analysis Kit (Clontech: 631263). The sequencing results were compared at NCBI with the CHO cell genome to obtain the lentiviral integration site information, which was located 101424 th base of CHO cell genome NW _003613756.1 in CHO-K1-1b7 cells.
Example 3: target sequence selection
According to the principle of being nearby, the CCTOP CRISPR/Cas9 is used for online predicting the sequences of 150bp upstream and downstream of 101424 base of a position NW _ 003613756.1: GTCTAGTCAACATTTTTATTCTTTCTTTTATGACATTCCCACTGGTGAACTTTGAACATATTTCAGTGGGGCTACTAATTTTTTTAACAAATTTTATTCTTCACGTGTTCATTATATAAGTCACAAAATTTTCTGTTCATTTTTATCTTTACTTAAGTGCTTCTCTTTTTGTATTGCCTGCATATGACTTTTAAATCTCCAAATTTTATTTTTTTTCCAACTTTTTTTATTTGAATTAGGAACAGGATTGTTTTACATGACAATCCCATTTCCCTTCTCCTACCCATCCTCCCCTACCTGC (SEQ ID NO.1), and selecting the target sequence with higher editing efficiency.
The relevant parameters are set as follows:
1) the maximum number of mismatch bases of the first 13bp allowed in the 20bp sequence after the NGG is 1;
2) and the number of mismatched bases of all 20bp after NGG is 4.
The CCTOP CRISPR/Cas9 online prediction system scores the editing efficiency of the identified 5'NNNNNNNNNNNNNNNNNNNNNGG 3' target sequence, LOW efficacy (score < 0.56); MEDIUM efficacy (0.56 ═ score ≦ 0.74); HIGH efficacy (score > 0.74).
Sequences in which the predicted editing efficiency was higher than 0.56 were selected as target sequences.
Target sequence 5'-TTCTTTTATGACATTCCCACTGG-3' (SEQ ID No.2), score 0.63
Target sequence 5'-ATATGTTCAAAGTTCACCAGTGG-3' (SEQ ID NO.3), score 0.79
Target sequence 5'-ACTTTGAACATATTTCAGTGGGG-3' (SEQ ID No.4), score 0.75
Target sequence 5'-GAGATTTAAAAGTCATATGCAGG-3' (SEQ ID No.5), score 0.57
Target sequence 5'-GTTGGAAAAAAAATAAAATTTGG-3' (SEQ ID No.6), score 0.62
Target sequence 5'-CAACTTTTTTTATTTGAATTAGG-3' (SEQ ID No.7), score 0.69
Target sequence 5'-TTTTTATTTGAATTAGGAACAGG-3' (SEQ ID No.8), score 0.56
Target sequence 5'-ATGGGTAGGAGAAGGGAAATGGG-3' (SEQ ID No.9), score 0.63
Target sequence 5'-GCAGGTAGGGGAGGATGGGTAGG-3' (SEQ ID No.10), score 0.62
Example 4: site-directed integration of EGFP
The CRISPR/Cas9 mediated genome site-directed editing technology and homologous recombination are utilized to integrate the green fluorescent protein gene (EGFP, 26.7KDa) at the target site in a site-directed manner. The CRISPR/Cas 9-mediated homologous recombination technology requires the construction of sgRNA Plasmid and Donor Plasmid, and the construction process is as follows:
1. sgRNA plasmid construction
1) Synthesis of an oligonucleotide chain according to the target sequence selected in example 3
sgRNA-F1 5'TTTGTTCTTTTATGACATTCCCACGT 3'(SEQ ID NO.11)
sgRNA-R1 5'TAAAACGTGGGAATGTCATAAAAGAA 3'(SEQ ID NO.12)
sgRNA-F2 5'TTTGATATGTTCAAAGTTCACCAG GT 3'(SEQ ID NO.13)
sgRNA-R2 5'TAAAACCTGGTGAACTTTGAACATAT 3'(SEQ ID NO.14)
sgRNA-F3 5'TTTGACTTTGAACATATTTCAGTG GT 3'(SEQ ID NO.15)
sgRNA-R3 5'TAAAACCACTGAAATATGTTCAAAGT 3'(SEQ ID NO.16)
sgRNA-F4 5'TTTGGAGATTTAAAAGTCATATGCGT 3'(SEQ ID NO.17)
sgRNA-R4 5'TAAAACGCATATGACTTTTAAATCTC 3'(SEQ ID NO.18)
sgRNA-F5 5'TTTGGTTGGAAAAAAAATAAAATTGT 3'(SEQ ID NO.19)
sgRNA-R5 5'TAAAACAATTTTATTTTTTTTCCAAC 3'(SEQ ID NO.20)
sgRNA-F6 5'TTTGCAACTTTTTTTATTTGAATTGT 3'(SEQ ID NO.21)
sgRNA-R6 5'TAAAACAATTCAAATAAAAAAAGTTG 3'(SEQ ID NO.22)
sgRNA-F7 5'TTTGTTTTTATTTGAATTAGGAACGT 3'(SEQ ID NO.23)
sgRNA-R7 5'TAAAACGTTCCTAATTCAAATAAAAA 3'(SEQ ID NO.24)
sgRNA-F8 5'TTTGATGGGTAGGAGAAGGGAAATGT 3'(SEQ ID NO.25)
sgRNA-R8 5'TAAAACATTTCCCTTCTCCTACCCAT 3'(SEQ ID NO.26)
sgRNA-F9 5'TTTGGCAGGTAGGGGAGGATGGGTGT 3'(SEQ ID NO.27)
sgRNA-R9 5'TAAAACACCCATCCTCCCCTACCTGC 3'(SEQ ID NO.28)
2) Annealing and connecting the synthesized oligonucleotide chains (1-9 pairs) respectively
Performing metal bath at 95 ℃ for 5min, and naturally cooling to room temperature;
3) carrying out enzyme digestion on the PSK-u6-gRNA plasmid by BBsI enzyme, and carrying out gel recovery on the vector subjected to enzyme digestion;
4) connecting the recovered plasmid vector with the annealed oligonucleotide chain
Ligation at 22 ℃ for 1h or overnight at 4 ℃;
5) transformation to DH5 α competence;
6) selecting positive clones, and sequencing by using a universal primer M13 fwd;
7) and expanding and culturing the positive clone bacterial strain and extracting plasmid.
2. Construction of Donor plasmid: the Donor plasmid information is shown in FIG. 1, and is obtained by modifying a plasmid vector expressing EGFP. The 5 'arm and the 3' arm are respectively an upstream homologous arm and a downstream homologous arm of the target site recognized by each pair of sgRNAs, the length is 600bp, and the GOI is an integrated target gene.
1) Obtaining 5 'arm and 3' arm with the length of 600bp upstream and downstream of the site with the plasmid homologous fragment through primer design and PCR amplification;
2) respectively utilizing double enzyme digestion and glue recovery to cut out the original homology arm of the Donor plasma;
3) respectively connecting 5 'arm and 3' arm corresponding to the target site by a homologous recombination method;
4) and the EGFP sequence of the target gene is carried by the original plasmid.
3. The constructed sgRNA plasmid, Donor plasmid and Cas9-DTU plasmid (donated by dr. helenef Kildegaard, denmark science and technology university) were transfected with Lipofectamine 3000 at a ratio of 1.8: the CHO-K1 cells cultured at 37 ℃ and 5% CO2 were CO-transfected at a mass ratio of 1.8:1, and a blank control was set. After 24h of transfection, pressure screening was performed using puromycin at 10. mu.g/ml until all the control cells were dead, the post-screening cell pool was expanded, and monoclonal cells emitting only green fluorescence and not emitting red fluorescence were sorted out using a BD flow cytometer.
4. After the cloning cell strain is expanded, a part of the extracted genome is identified by 5 'Junction PCR, 3' Junction PCR and out-out PCR, as shown in FIG. 1.
5. The positive clone cell line was retained.
Example 5: fixed point integration of IL2-HSA
The gene (IL2-HSA, 82KDa) for expressing the interferon-beta-human serum albumin fusion protein is integrated at a target site in a fixed point manner by using a CRISPR/Cas9 mediated genome fixed point editing technology and a homologous group. The CRISPR/Cas 9-mediated homologous recombination technology requires the construction of sgRNA Plasmid and Donor Plasmid, and the construction process is as follows:
1. construction of sgRNA plasmid:
1) synthesis of an oligonucleotide chain according to the target sequence selected in example 3
sgRNA-F1 5'TTTGTTCTTTTATGACATTCCCACGT 3'
sgRNA-R1 5'TAAAACGTGGGAATGTCATAAAAGAA 3'
sgRNA-F2 5'TTTGATATGTTCAAAGTTCACCAG GT 3'
sgRNA-R2 5'TAAAACCTGGTGAACTTTGAACATAT 3'
sgRNA-F3 5'TTTGACTTTGAACATATTTCAGTG GT 3'
sgRNA-R3 5'TAAAACCACTGAAATATGTTCAAAGT 3'
sgRNA-F4 5'TTTGGAGATTTAAAAGTCATATGCGT 3'
sgRNA-R4 5'TAAAACGCATATGACTTTTAAATCTC 3'
sgRNA-F5 5'TTTGGTTGGAAAAAAAATAAAATTGT 3'
sgRNA-R5 5'TAAAACAATTTTATTTTTTTTCCAAC 3'
sgRNA-F6 5'TTTGCAACTTTTTTTATTTGAATTGT 3'
sgRNA-R6 5'TAAAACAATTCAAATAAAAAAAGTTG 3'
sgRNA-F7 5'TTTGTTTTTATTTGAATTAGGAACGT 3'
sgRNA-R7 5'TAAAACGTTCCTAATTCAAATAAAAA 3'
sgRNA-F8 5'TTTGATGGGTAGGAGAAGGGAAATGT 3'
sgRNA-R8 5'TAAAACATTTCCCTTCTCCTACCCAT 3'
sgRNA-F9 5'TTTGGCAGGTAGGGGAGGATGGGTGT 3'
sgRNA-R9 5'TAAAACACCCATCCTCCCCTACCTGC 3'
2) Annealing and connecting the synthesized oligonucleotide chains (1-9 pairs) respectively
Performing metal bath at 95 ℃ for 5min, and naturally cooling to room temperature;
3) carrying out enzyme digestion on the PSK-u6-gRNA plasmid by BBsI enzyme, and carrying out gel recovery on the vector subjected to enzyme digestion;
4) connecting the recovered plasmid vector with the annealed oligonucleotide chain
Ligation at 22 ℃ for 1h or overnight at 4 ℃;
5) transformation to DH5 α competence;
6) selecting positive clones, and sequencing by using a universal primer M13 fwd;
7) expanding and culturing the positive cloned strains and improving the quality;
2. construction of Donor Plasmid: the Donor plasma information is shown in fig. 1. The 5 'arm and the 3' arm are respectively an upstream homologous arm and a downstream homologous arm of the target site, the length is 600bp, and the GOI is an integrated target gene.
1) Obtaining 5 'arm and 3' arm with the length of 600bp upstream and downstream of the site with the plasmid homologous fragment through primer design and PCR amplification;
2) respectively utilizing double enzyme digestion and glue recovery to cut out the original homology arm of the Donor plasmid;
3) respectively connecting 5 'arm and 3' arm corresponding to the target site by a homologous recombination method;
4) and obtaining the target gene IL2-HSA through PCR amplification, and connecting the target gene IL2-HSA to a plasmid vector by utilizing enzyme digestion linkage.
3. The constructed sgRNA plasmid, Donor plasmid and Cas9-DTU plasmid (donated by dr. helene F Kildegaard, denmark science and technology university) were transfected with Lipofectamine 3000 transfection reagent at 1.8: 1.8:1 mass ratio cotransfected at 37 ℃ with 5% CO2CHO-K1 cells cultured under conditions, while a blank control was set. After 24h of transfection, pressure screening was performed using puromycin at 10. mu.g/ml until all cells in the control group died, the post-screening cell pool was expanded and monoclonal cells that did not fluoresce were sorted out using a BD flow cytometer.
4. After the cloning cell strain is expanded, a part of the extracted genome is identified by 5 'Junction PCR, 3' Junction PCR and out-out PCR, as shown in FIG. 1.
5. The positive clone cell line was retained.
Test example:
1. the green fluorescence intensity of the cell line constructed in example 4 was measured by a BD flow cytometer
The detection method comprises the following steps: the cell strains obtained in example 4 are continuously passaged for 60 generations, cells are collected every 15 generations, cell fluorescence is detected by a flow cytometer, and the intensity is detected, as shown in fig. 2, the detection result shows that more than 98% of the cells constructed according to different target sequences in example 4 still express green fluorescent protein after the cells are continuously passaged for 60 generations, and the fluctuation range of the green fluorescent intensity between 0 generation and 60 generation does not exceed 30%.
2. Urine microalbumin assay kit detection of IL2-HSA expression level in the cell line constructed in example 5
The detection method comprises the following steps: the cell strains obtained in example 5 were continuously passaged for 60 generations under serum-free culture conditions, cell fermentation supernatants were collected every 15 generations, and HSA content in the fermentation broth was determined using a urine microalbumin assay kit (nmg/L, according to
The expression level of IL2-HSA was calculated, and the analysis of the assay results showed that the cells constructed according to the different target sequences in example 5 had stable ability to express IL2-HSA in different generations, as shown in FIG. 3.
In the embodiment of the invention, the CRISPR/Cas 9-mediated genome site-directed editing technology is mainly used for site-directed integration, so that the target sequences are mainly designed aiming at the upstream and downstream sequences within 300bp bases, 9 groups of target sequences screened in the embodiment 3 of the invention cover most of the upstream and downstream sequences within 300bp bases, and the 101274-19 base range and the 101574 base range in the CHO cell gene NW _003613756.1 of the invention can successfully construct a site-directed integrated stable expression cell line and can stably express the target protein.
The above-mentioned embodiments are merely preferred embodiments for fully illustrating the present invention, and the scope of the present invention is not limited thereto. The equivalent substitution or change made by the technical personnel in the technical field on the basis of the invention is all within the protection scope of the invention. The protection scope of the invention is subject to the claims.
Sequence listing
<110> university of south of the Yangtze river
<120> site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof
<160> 28
<170> SIPOSequenceListing 1.0
<210> 1
<211> 301
<212> DNA
<213> (Artificial sequence)
<400> 1
gtctagtcaa catttttatt ctttctttta tgacattccc actggtgaac tttgaacata 60
tttcagtggg gctactaatt tttttaacaa attttattct tcacgtgttc attatataag 120
tcacaaaatt ttctgttcat ttttatcttt acttaagtgc ttctcttttt gtattgcctg 180
catatgactt ttaaatctcc aaattttatt ttttttccaa ctttttttat ttgaattagg 240
aacaggattg ttttacatga caatcccatt tcccttctcc tacccatcct cccctacctg 300
c 301
<210> 2
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 2
ttcttttatg acattcccac tgg 23
<210> 3
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 3
atatgttcaa agttcaccag tgg 23
<210> 4
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 4
actttgaaca tatttcagtg ggg 23
<210> 5
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 5
gagatttaaa agtcatatgc agg 23
<210> 6
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 6
gttggaaaaa aaataaaatt tgg 23
<210> 7
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 7
caactttttt tatttgaatt agg 23
<210> 8
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 8
tttttatttg aattaggaac agg 23
<210> 9
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 9
atgggtagga gaagggaaat ggg 23
<210> 10
<211> 23
<212> DNA
<213> (Artificial sequence)
<400> 10
gcaggtaggg gaggatgggt agg 23
<210> 11
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 11
tttgttcttt tatgacattc ccacgt 26
<210> 12
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 12
taaaacgtgg gaatgtcata aaagaa 26
<210> 13
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 13
tttgatatgt tcaaagttca ccaggt 26
<210> 14
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 14
taaaacctgg tgaactttga acatat 26
<210> 15
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 15
tttgactttg aacatatttc agtggt 26
<210> 16
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 16
taaaaccact gaaatatgtt caaagt 26
<210> 17
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 17
tttggagatt taaaagtcat atgcgt 26
<210> 18
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 18
taaaacgcat atgactttta aatctc 26
<210> 19
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 19
tttggttgga aaaaaaataa aattgt 26
<210> 20
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 20
taaaacaatt ttattttttt tccaac 26
<210> 21
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 21
tttgcaactt tttttatttg aattgt 26
<210> 22
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 22
taaaacaatt caaataaaaa aagttg 26
<210> 23
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 23
tttgttttta tttgaattag gaacgt 26
<210> 24
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 24
taaaacgttc ctaattcaaa taaaaa 26
<210> 25
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 25
tttgatgggt aggagaaggg aaatgt 26
<210> 26
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 26
taaaacattt cccttctcct acccat 26
<210> 27
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 27
tttggcaggt aggggaggat gggtgt 26
<210> 28
<211> 26
<212> DNA
<213> (Artificial sequence)
<400> 28
taaaacaccc atcctcccct acctgc 26
Claims (7)
1. The application of a site for stably expressing a protein in a CHO cell gene NW _003613756.1 in stably expressing a foreign protein or polypeptide in a CHO cell is characterized in that a gene encoding the foreign protein or polypeptide is integrated into the site for stably expressing the protein in the CHO cell gene NW _003613756.1, and the site for stably expressing the protein is positioned in the 101274-19 101574 base of the CHO cell gene NW _ 003613756.1.
2. The use according to claim 1, wherein the site of stable protein expression is recognized by CRISPR/Cas9 technology with 5'NNNNNNNNNNNNNNNNNNNNNGG 3' as target sequence.
3. The use according to claim 1, wherein the protein is a protein having a molecular weight of less than 160 KDa.
4. An expression vector for expressing a protein in CHO cells, wherein a gene encoding the protein is located in a region between a 5 'homology arm and a 3' homology arm of the expression vector, and the 5 'homology arm and the 3' homology arm are sequences having a length of 600bp upstream and downstream of the site where the protein is stably expressed according to claim 1.
5. The expression vector of claim 4, further comprising a promoter sequence upstream of the gene encoding the protein, wherein the promoter controls expression of the protein.
6. The expression vector of claim 5, wherein the promoter is: one of a human cytomegalovirus-derived strong mammalian expression promoter, a human elongation factor 1 α -derived strong mammalian expression promoter, a simian vacuolating virus 40-derived mammalian expression promoter, a phosphoglycerate kinase gene-derived mammalian promoter, a human ubiquitin C gene-derived mammalian promoter, a β -actin gene-derived mammalian promoter, and a strong hybrid mammalian promoter.
7. A CHO recombinant cell for expressing a protein in a site-specific integration manner, which is obtained by transferring the expression vector for expressing the protein in the CHO cell according to claim 4, a sgRNA plasmid corresponding to a target sequence and a Cas9 plasmid into the CHO cell, wherein the target sequence is shown as 5'NNNNNNNNNNNNNNNNNNNNNGG 3' in the specification.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111395490.6A CN113969283B (en) | 2021-11-23 | 2021-11-23 | Site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof |
| PCT/CN2022/099460 WO2023093005A1 (en) | 2021-11-23 | 2022-06-17 | Site capable of stably expressing protein in cho cell gene nw_003613756.1 and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111395490.6A CN113969283B (en) | 2021-11-23 | 2021-11-23 | Site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113969283A CN113969283A (en) | 2022-01-25 |
| CN113969283B true CN113969283B (en) | 2022-07-12 |
Family
ID=79590150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111395490.6A Active CN113969283B (en) | 2021-11-23 | 2021-11-23 | Site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113969283B (en) |
| WO (1) | WO2023093005A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113969284B (en) * | 2021-11-23 | 2022-07-12 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003614889.1 and application thereof |
| CN113969283B (en) * | 2021-11-23 | 2022-07-12 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104818253A (en) * | 2015-03-24 | 2015-08-05 | 成都贝爱特生物科技有限公司 | Reconstruction and application of targeted site-specific integrated CHO cell line |
| CN107557390A (en) * | 2017-09-18 | 2018-01-09 | 江南大学 | A kind of method for screening the high expression sites of Chinese hamster ovary celI system |
| CN109295092A (en) * | 2018-10-30 | 2019-02-01 | 江南大学 | NW_003613638-1 stablizes the application of expression protein in a kind of CHO cell genome |
| CN110914413A (en) * | 2017-02-17 | 2020-03-24 | 隆萨有限公司 | Mammalian cell producing adeno-associated virus |
| CN113969284A (en) * | 2021-11-23 | 2022-01-25 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003614889.1 and application thereof |
| CN114058625A (en) * | 2021-11-25 | 2022-02-18 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003613781.1 and application thereof |
| CN114085841A (en) * | 2021-11-23 | 2022-02-25 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003614092.1 and application thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106554943A (en) * | 2015-09-30 | 2017-04-05 | 北京吉尚立德生物科技有限公司 | A kind of Chinese hamster ovary celI strain CHO-Creb3L1 of restructuring overexpression Creb3L1 genes |
| CN107723276B (en) * | 2017-11-02 | 2021-08-13 | 上海交通大学 | Construction method and kit for cell strain of stable high-expression target product |
| WO2019237369A1 (en) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | Construction method of cho cell strain having site-specific inserted cdw137 gene and use thereof |
| CN109321604B (en) * | 2018-10-30 | 2021-07-06 | 江南大学 | Application of NW _006882077-1 stable expression protein in CHO cell genome |
| CN109136193B (en) * | 2018-10-30 | 2021-07-06 | 江南大学 | Application of NW _006884764-1 stable expression protein in CHO cell genome |
| CN109295093B (en) * | 2018-10-30 | 2021-08-03 | 江南大学 | Application of NW _006882456-1 stable expression protein in CHO cell genome |
| CN109207432B (en) * | 2018-10-30 | 2021-08-03 | 江南大学 | Application of NW _006883358-1 stable expression protein in CHO cell genome |
| CN109337927B (en) * | 2018-10-30 | 2021-07-06 | 江南大学 | Application of NW _006880285-1 stable expression protein in CHO cell genome |
| CN113969283B (en) * | 2021-11-23 | 2022-07-12 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof |
-
2021
- 2021-11-23 CN CN202111395490.6A patent/CN113969283B/en active Active
-
2022
- 2022-06-17 WO PCT/CN2022/099460 patent/WO2023093005A1/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104818253A (en) * | 2015-03-24 | 2015-08-05 | 成都贝爱特生物科技有限公司 | Reconstruction and application of targeted site-specific integrated CHO cell line |
| CN110914413A (en) * | 2017-02-17 | 2020-03-24 | 隆萨有限公司 | Mammalian cell producing adeno-associated virus |
| CN107557390A (en) * | 2017-09-18 | 2018-01-09 | 江南大学 | A kind of method for screening the high expression sites of Chinese hamster ovary celI system |
| CN109295092A (en) * | 2018-10-30 | 2019-02-01 | 江南大学 | NW_003613638-1 stablizes the application of expression protein in a kind of CHO cell genome |
| CN113969284A (en) * | 2021-11-23 | 2022-01-25 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003614889.1 and application thereof |
| CN114085841A (en) * | 2021-11-23 | 2022-02-25 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003614092.1 and application thereof |
| CN114058625A (en) * | 2021-11-25 | 2022-02-18 | 江南大学 | Site for stably expressing protein in CHO cell gene NW _003613781.1 and application thereof |
Non-Patent Citations (7)
| Title |
|---|
| CHO 细胞Kcmf1 基因内定点整合ZsGreen1报告基因的表达稳定性研究;杨蕾等;《食品与生物技术学报》;20210415;第40卷(第4期);58-66 * |
| Cricetulus griseus genome assembly, contig: contig_4588, whole genome shotgun sequence;NCBI;《Genbank database》;20170615;FYBK01004588.1 * |
| Cricetulus griseus unplaced genomic scaffold, CriGri_1.0 scaffold2157, whole genome shotgunsequence;NCBI;《Genbank database》;20200710;NW_003613756.1 * |
| Discovery of a stable expression hot spot in the genome of Chinese hamster ovary cells using lentivirus-based random integration;Songtao Zhou等;《Biotechnology & Biotechnological Equipment》;20190421;第33卷(第1期);605-612 * |
| 克服位置效应提高外源基因在CHO细胞中稳定高效表达的策略;周宏等;《生物技术通讯》;20061230;第17卷(第06期);945-949 * |
| 利用CRISPR/Cas9技术构建稳定表达人白蛋白基因的中国仓鼠卵巢细胞系;周松涛等;《中国生物工程杂志》;20190415(第04期);52-59 * |
| 外源蛋白在CHO细胞染色体上一个新位点的定点整合和稳定表达;胡湾湾等;《中国药科大学学报》;20210825;第52卷(第4期);487-495 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023093005A1 (en) | 2023-06-01 |
| CN113969283A (en) | 2022-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114085841B (en) | Site for stably expressing protein in CHO cell gene NW _003614092.1 and application thereof | |
| CN114058625B (en) | Site for stably expressing protein in CHO cell gene NW _003613781.1 and application thereof | |
| CN106191116B (en) | Foreign gene based on CRISPR/Cas9 knocks in integration system and its method for building up and application | |
| CN113969283B (en) | Site for stably expressing protein in CHO cell gene NW _003613756.1 and application thereof | |
| CN113969284B (en) | Site for stably expressing protein in CHO cell gene NW _003614889.1 and application thereof | |
| CN109136193B (en) | Application of NW _006884764-1 stable expression protein in CHO cell genome | |
| CN107893073B (en) | Method for screening glutamine synthetase defect type HEK293 cell strain | |
| US11732276B2 (en) | Use of genomic NW_006882077.1 in CHO cell for stably expressing a protein | |
| WO2019120193A1 (en) | Split single-base gene editing systems and application thereof | |
| CN109295092B (en) | Application of NW _003613638-1 stable expression protein in CHO cell genome | |
| CN111254164A (en) | Method for rapidly establishing CRISPR gene editing liver cancer cell strain and cell strain | |
| US11692204B2 (en) | Use of genomic NW_006880285.1 in CHO cell for stably expressing a protein | |
| CN109295093B (en) | Application of NW _006882456-1 stable expression protein in CHO cell genome | |
| CN109207432B (en) | Application of NW _006883358-1 stable expression protein in CHO cell genome | |
| EP4308699A1 (en) | Multiplex editing with cas enzymes | |
| CN109402096A (en) | A kind of AID enzyme mutant and its application | |
| JP3415840B2 (en) | Method for producing foreign protein | |
| CN117683813A (en) | EE0.6 site knockout vector and NC_006127.4 site knockout vector in DF-1 cells | |
| CN114540308A (en) | Cell line for stably expressing orthogonal aminoacyl tRNA synthetase/tRNA and construction method | |
| JP2022543522A (en) | Cell lines for high-level production of protein-based pharmaceuticals | |
| CN116875597A (en) | Vector for correcting LMNA cardiomyopathy pathogenic mutation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |